Year 2 Prime Therapeutics’ leading research shows 1 in 12 remain on a GLP-1 drug for obesity at three years. Findings also show improved persistence with high-potency, obesity-approved GLP-1...

Jessica Johnson, clinical consultant at Prime Therapeutics, shares more about common GLP-1 fraud schemes

Real-world study of GLP-1 patients continues to deliver leading insights

Findings also show improved persistence with high-potency, obesity-approved GLP-1 products